A study on the long-term safety of dupilumab, a treatment for moderate to severe asthma, found that it appeared safe for long-term use. The study included 393 participants who received 300 mg doses every 2 weeks for up to 3 years. The median treatment duration was 309 days, and the exposure-adjusted event rate for serious adverse events was 6.9 per 100 patient-years. Overall, the safety profile and tolerability observed during long-term treatment for an additional 3 years affirmed the overall long-term safety and tolerability of dupilumab. The study was consistent with the safety profile observed in previous studies.
Source link
Dupilumab safe for long-term use to treat moderate to severe asthma
